Simplex Trading’s Neuropace NPCE Stock Holding History

Simplex Trading’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$1K	–	9574
2025 Q3	$1K	Hold	100	–	–	﹤0.01%	8845
2025 Q2	$1K	Buy	+100	New	+$1.25K	﹤0.01%	8381

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Simplex Trading's NPCE Position: Q3 2025 in Review

Simplex Trading sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 1,895 shares — an estimated $17.9K sold.

Simplex Trading first reported a position in NPCE in Q2 2024 and held it in 4 quarters. The position peaked at $21K in Q2 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

Simplex Trading reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
Simplex Trading sold 1,895 Neuropace shares in Q3 2025, an estimated $17.9K.
Simplex Trading first reported a position in Neuropace in Q2 2024 and held it in 4 quarters.
Simplex Trading's Neuropace position peaked at $21K in Q2 2025.
80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.